Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mycural Therapeutics has 1 pending office action in Biotechnology & Pharmaceuticals. The portfolio is handled by 1 distinct examiner in 1 distinct art unit, so the pending matter follows a single examination channel.
RICCI, CRAIG D is the busiest examiner, with 1 pending matter. Preparation can be directed toward the identified action and the examination approach associated with that examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RICCI, CRAIG D | 1 | 53.7% | +52.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721989 | NOVEL PYRIDOCARBAZOLIUM COMPOUNDS AND MEDICAL USES THEREOF | RICCI, CRAIG D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721989 | NOVEL PYRIDOCARBAZOLIUM COMPOUNDS AND MEDICAL USES THEREOF | RICCI, CRAIG D | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18721989 | NOVEL PYRIDOCARBAZOLIUM COMPOUNDS AND MEDICAL USES THEREOF | RICCI, CRAIG D | 1611 | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMycural Therapeutics has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Craig D Ricci has the most, with 1 of Mycural Therapeutics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.